Data on the stability of darunavir/cobicistat suspension after tablet manipulation
The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Series: | Data in Brief |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340920304467 |
| _version_ | 1811222914883649536 |
|---|---|
| author | D. Zanon A. Manca A. De Nicolò A. D'Avolio U.M. Musazzi F. Cilurzo N. Maximova C. Tomasello P. Minghetti |
| author_facet | D. Zanon A. Manca A. De Nicolò A. D'Avolio U.M. Musazzi F. Cilurzo N. Maximova C. Tomasello P. Minghetti |
| author_sort | D. Zanon |
| collection | DOAJ |
| description | The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients’ need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week. |
| first_indexed | 2024-04-12T08:24:16Z |
| format | Article |
| id | doaj.art-4c734a47db8a4e33bdf45ab59bb275d6 |
| institution | Directory Open Access Journal |
| issn | 2352-3409 |
| language | English |
| last_indexed | 2024-04-12T08:24:16Z |
| publishDate | 2020-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Data in Brief |
| spelling | doaj.art-4c734a47db8a4e33bdf45ab59bb275d62022-12-22T03:40:28ZengElsevierData in Brief2352-34092020-06-0130105552Data on the stability of darunavir/cobicistat suspension after tablet manipulationD. Zanon0A. Manca1A. De Nicolò2A. D'Avolio3U.M. Musazzi4F. Cilurzo5N. Maximova6C. Tomasello7P. Minghetti8Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, ItalyLaboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, ItalyLaboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, ItalyLaboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, ItalyDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, ItalyDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, ItalyInstitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, ItalyS.C. Farmacie Ospedaliere - Ospedale M. Vittoria - Asl Città di Torino, Turin, ItalyDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, Via Giuseppe Colombo, 71, 20133 Milan, Italy; Corresponding author.The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients’ need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week.http://www.sciencedirect.com/science/article/pii/S2352340920304467Covid-19Medicament manipulationNasogastric tubeDarunavirCobicistat |
| spellingShingle | D. Zanon A. Manca A. De Nicolò A. D'Avolio U.M. Musazzi F. Cilurzo N. Maximova C. Tomasello P. Minghetti Data on the stability of darunavir/cobicistat suspension after tablet manipulation Data in Brief Covid-19 Medicament manipulation Nasogastric tube Darunavir Cobicistat |
| title | Data on the stability of darunavir/cobicistat suspension after tablet manipulation |
| title_full | Data on the stability of darunavir/cobicistat suspension after tablet manipulation |
| title_fullStr | Data on the stability of darunavir/cobicistat suspension after tablet manipulation |
| title_full_unstemmed | Data on the stability of darunavir/cobicistat suspension after tablet manipulation |
| title_short | Data on the stability of darunavir/cobicistat suspension after tablet manipulation |
| title_sort | data on the stability of darunavir cobicistat suspension after tablet manipulation |
| topic | Covid-19 Medicament manipulation Nasogastric tube Darunavir Cobicistat |
| url | http://www.sciencedirect.com/science/article/pii/S2352340920304467 |
| work_keys_str_mv | AT dzanon dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT amanca dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT adenicolo dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT adavolio dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT ummusazzi dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT fcilurzo dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT nmaximova dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT ctomasello dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation AT pminghetti dataonthestabilityofdarunavircobicistatsuspensionaftertabletmanipulation |